Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Adicionar filtros








Intervalo de ano
1.
Journal of Experimental Hematology ; (6): 80-84, 2017.
Artigo em Chinês | WPRIM | ID: wpr-311590

RESUMO

<p><b>OBJECTIVE</b>To explore the effect of homoharringtonine(HHT) combined with imatinib(IM) on proliferation and apoptosis of K562/G01 cells and its potential mechanism.</p><p><b>METHODS</b>K562/G01 cells were cultured with HHT and/or IM. CCK-8 assay was used to detect cell proliferation. Cell apoptosis and phosphorylated tyrosine levels were analyzed by flow cytometry. The expression levels of p210, PI3K, p-Akt and Akt protein were determined by Western blot.</p><p><b>RESULTS</b>Compared with HHT or IM alone, drug combination significantly inhibited cell proliferation and induced apoptosis of K562/G01 cells (both P< 0.05). HHT combined with IM could inhibit the levels of phosphorylated tyrosine and phosphorylated Crkl and downregulate the expressions of p210, PI3K and p-Akt in K562/G01 cells.</p><p><b>CONCLUSION</b>HHT combined with IM can synergistically inhibit proliferation and induce apoptosis of K562/G01 cells by suppressing the p210 expression and its kinase activity.</p>

2.
Journal of Experimental Hematology ; (6): 412-417, 2017.
Artigo em Chinês | WPRIM | ID: wpr-311528

RESUMO

<p><b>OBJECTIVE</b>To study the effect of homoharringtonine (HHT) alone or combined with 3-methyladenine (3-MA) , an autophagy inhibitor, on the apoptosis and autophagy of K562 cells.</p><p><b>METHODS</b>K562 cells were treated with HHT(10 ng/ml) or HHT(10 ng/ml) combined with 3-MA (1.5 mmol/L) for 1 to 8 days. The apoptosis of treated cells was tested by means of flow cytometry(FCM), and the autophagy levels were tested with RT-PCR, Western blot and electron microscopy.</p><p><b>RESULTS</b>In the early stage of HHT-treated group, the apoptosis rate increased and decreased later. Beclin1 mRNA expression level and the LC3II/I ratio were declined firstly and increased later in HHT group. While combining with autophagy inhibitor 3-MA, both the Beclin1 mRNA expression level and the LC3II/I ratio were declined continually during the treated period. The activated caspase-3 protein expression level was also raised sustainability during both HHT and 3-MA cultured period.</p><p><b>CONCLUSIONS</b>HHT can induce apoptosis of K562 cells, but the sustaining effect of HHT can induc autophagy of K562 cells, the combination of HHT with 3-MA may enhance the cytotoxicitic effect of HHT on K562 cells.</p>

3.
Journal of Experimental Hematology ; (6): 712-716, 2014.
Artigo em Chinês | WPRIM | ID: wpr-302412

RESUMO

This study was aimed to explore the change of K562 cell apoptosis at different time point after homoharringtonine (HHT) treatment and its mechanism. After treatment of K562 cells with 10 ng/ml HHT, the cell viability was tested with MTT assay; the expression of caspase-3 was detected with Western blot; the BCL-2 expression was analyzed with flow cytometry; the autophagosome was observed by electron microscopy. The results showed that the viability of K562 cells reduced gradually from day 1 to day 5 and ascended from day 6 to day 8 after HHT treatment. At the same time, the cleaved caspase-3 expression level of K562 cells increased gradually from day 1 to day 7, but reduced at the day 8 (P < 0.05). From day 1 to day 8 after HHT treatment, the BCL-2 expression level declined firstly and then went up (P < 0.05). Autophagosome was also seen remarkably at day 8 after HHT treatment. It is concluded that the apoptosis level of K562 cells after being treated with HHT enhances firstly and then declines , which may be associated with higher autophagy level in the late stage of HHT treatment.


Assuntos
Humanos , Apoptose , Autofagia , Caspase 3 , Metabolismo , Proliferação de Células , Citometria de Fluxo , Harringtoninas , Farmacologia , Células K562 , Proteínas Proto-Oncogênicas c-bcl-2 , Metabolismo
4.
Journal of Zhejiang University. Medical sciences ; (6): 192-195, 2012.
Artigo em Chinês | WPRIM | ID: wpr-336810

RESUMO

<p><b>OBJECTIVE</b>To investigate plasma gamma-glutamyl transpeptidase (γ-GGT) level as a cardiovascular risk factor in elderly patients with hypertension or hypertension with diabetes mellitus.</p><p><b>METHODS</b>Forty-nine elderly patients of hypertension and 42 elderly patients of hypertension with diabetes mellitus and 39 healthy elderly subjects were enrolled in the study. The height, weight and blood pressure of patients were measured, serum C reactive protein and other biochemical indicators were detected. The relation between plasma γ-GGT and cardiovascular risk factors in three groups were analyzed.</p><p><b>RESULTS</b>There was no significant difference in plasma γ-GGT levels among three groups. There was a positive correlation of plasma γ-GGT levels with systolic pressure, pulse pressure, hemoglobin A1c and CRP in control group. While in hypertension with diabetes mellitus group, plasma γ-GGT levels were correlated with systolic pressure, mean arterial pressure, fasting blood sugar and cystatin.</p><p><b>CONCLUSION</b>Plasma γ-GGT might be a risk factor for cardiovascular diseases, and may be used as a predictive indicator for kidney injury in early patients with hypertension with diabetes mellitus.</p>


Assuntos
Idoso , Idoso de 80 Anos ou mais , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Doenças Cardiovasculares , Estudos de Casos e Controles , Diabetes Mellitus , Hipertensão , Fatores de Risco , gama-Glutamiltransferase , Sangue
5.
Journal of Zhejiang University. Medical sciences ; (6): 198-201, 2010.
Artigo em Chinês | WPRIM | ID: wpr-259217

RESUMO

<p><b>OBJECTIVE</b>To evaluate the effect of intensive treatment on the blood sugar, blood lipids and blood pressure levels in incipient diabetes II patients.</p><p><b>METHODS</b>One hundred and sixty incipient diabetes patients were allocated into two groups according to chronological order: 80 cases received routine treatment and 80 cases received intensive treatment. Fasting blood-glucose (FBG), glycosylated hemoglobin (HbA1C), blood pressure, blood cholesterol (TC), triglyceride (TG), LDL cholesterol-C (LDL-C), alanine aminotransferase (ALT) and aspertate aminotransferase (AST) were tested before treatment. For intensive treatment group blood pressure, blood sugar and blood lipids were regularly tested, and the therapeutic protocols were adjusted according to the test results until the therapeutic target reached. After six months, HbA1C, blood pressure, TC, LDL-C, ALT and AST were tested again and comparison was made between the two groups.</p><p><b>RESULTS</b>There was a significant decrease in TC and LDL-C in the intensive treatment group compared with those in the routine treatment group (P <0.05).</p><p><b>CONCLUSION</b>The intensive treatment on the incipient diabetes II patients facilitate the control of the blood lipids and blood sugar.</p>


Assuntos
Adulto , Idoso , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Glicemia , Pressão Sanguínea , Diabetes Mellitus Tipo 2 , Tratamento Farmacológico , Hipoglicemiantes , Usos Terapêuticos , Lipídeos , Sangue
6.
Journal of Zhejiang University. Medical sciences ; (6): 339-341, 2003.
Artigo em Chinês | WPRIM | ID: wpr-231053

RESUMO

<p><b>OBJECTIVE</b>To investigate the effect of thymosin alpha 1 on cellular immune function in the elderly patients with malignant tumor.</p><p><b>METHODS</b>Thirty patients with malignant tumor were injected with thymosin alpha 1 subcutaneously at the dose of 1.6 mg q.d. for the first month and q.o.d. for the following month. The number of T cell subgroups and the activity of NK cell in peripheral blood were detected and the quality of life of the patients were evaluated before treatment and at the end of treatment.</p><p><b>RESULT</b>Treatment of thymosin alpha 1 increased the number of CD4 cells and improved the NK activity, and also improved the quality of life of the elderly patients with malignant tumor. There were no side effects found.</p><p><b>CONCLUSION</b>Thymosin alpha 1 can enhance the cellular immune function of the elderly patients with malignant tumor.</p>


Assuntos
Idoso , Idoso de 80 Anos ou mais , Feminino , Humanos , Masculino , Contagem de Linfócito CD4 , Células Matadoras Naturais , Alergia e Imunologia , Neoplasias , Tratamento Farmacológico , Alergia e Imunologia , Psicologia , Qualidade de Vida , Timosina , Farmacologia , Usos Terapêuticos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA